ArticleDrug and alcohol dependence2013
Patterns of nicotinic receptor antagonism II: cardiovascular effects in rats.
Article in Drug and alcohol dependence, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of the American Heart Association · 2016Pooled it
- Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy.BMJ (Clinical research ed.) · 2014Trial
- Blockers of Acetylcholine Receptors Affect the Hypotensive Effect of the Central Loop Fragment of the WTX Toxin.Doklady. Biochemistry and biophysics · 2026Article
- Copper-Mediated Homocoupling ofMolecules (Basel, Switzerland) · 2025Article
- Examination of Serum Metabolome Altered by Dietary Carbohydrate, Milk Protein, and Soy Protein Interventions Identified Novel Metabolites Associated with Blood Pressure: The ProBP Trial.Molecular nutrition & food research · 2023Article
- Potential uses of cytisine for smoking cessation in menopausal women - literature summary.Przeglad menopauzalny = Menopause review · 2023Article
- Characterization of Ultrapotent Chemogenetic Ligands for Research Applications in Nonhuman Primates.ACS chemical neuroscience · 2022Article
- Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition.The Journal of pharmacology and experimental therapeutics · 2021Article
- Partial Agonist Activity of Neonicotinoids on Rat Nicotinic Receptors: Consequences over Epinephrine Secretion and In Vivo Blood Pressure.International journal of molecular sciences · 2021Article
- Comparison of the muscarinic antagonist effects of scopolamine and L-687,306.Behavioural pharmacology · 2020Article
- Rapid nicotine tolerance and cross-tolerance to varenicline in rhesus monkeys: Drug discrimination.Experimental and clinical psychopharmacology · 2018Article
- Nicotine plus a high-fat diet triggers cardiomyocyte apoptosis.Cell and tissue research · 2017Article
- Connection of Nicotine to Diet-Induced Obesity and Non-Alcoholic Fatty Liver Disease: Cellular and Mechanistic Insights.Frontiers in endocrinology · 2017Review
- The Impact of Environmental Factors in Influencing Epigenetics Related to Oxidative States in the Cardiovascular System.Oxidative medicine and cellular longevity · 2017Review
- Evaluation of the cardiovascular effects of varenicline in rats.Drug design, development and therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundTobacco cessation pharmacotherapies currently are limited to nicotine itself, the partial nicotine agonists varenicline and cytisine, and the antidepressant bupropion. Compared with agonists, nicotinic antagonists such as the noncompetitive, nonselective compound mecamylamine, and the competitive, α4β2-preferring antagonist dihydro-β-erythroidine (DHβE) may be a novel approach to the treatment of tobacco smoking as both are effective antagonists of nicotine's central effects. Considering nicotinic acetylcholine receptors mediate critical peripheral effects of acetylcholine, such as cardiovascular effects, it is important to study how nicotinic antagonists would alter the cardiovascular system and the cardiovascular changes induced by nicotine.
methodsThe effects of several nicotinic agonists and antagonists on blood pressure and heart rate were measured in conscious, unrestrained rats following parenteral administration using a telemetry system.
resultsNicotine and other nicotinic receptor agonists (epibatidine, varenicline, and cytisine) produced similar increases in blood pressure, whereas their effects on heart rate were biphasic. The cardiovascular changes were attenuated by the nonselective nicotine antagonist, mecamylamine, but the peripherally restricted antagonist hexamethonium blocked only the agonist-induced changes in blood pressure. The α7-preferring antagonist, MLA, and the α4β2-preferring antagonist, DHβE, were much less effective in blocking the agonist-induced cardiovascular changes, indicating that nicotine's cardiovascular effects, are due to activation at autonomic ganglia involving nicotinic receptor subtypes other than α4, α7, or β2.
conclusionsThe data indicate that the cardiovascular effects of nicotine and nicotine-like agents are mediated through receptor mechanisms that are distinct from those that mediate the central effects of nicotine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.